FDA Finds No Misconduct by Care Access in Pfizer’s Lyme Vaccine Tria

2023年10月16日 22:06:57

打印 放大 缩小

Following Pfizer’s abrupt discontinuation of Care Access study participants,
the FDA inspection finds no violations

BOSTON--(BUSINESS WIRE)--Care Access announced today the completion of a for-cause Food and Drug Administration (“FDA”) Good Clinical Practices (“GCP”) inspection related to Care Access’s activities on the Pfizer VALOR trial. The inspection resulted in no FDA Form 483 observations, meaning the FDA investigator found no GCP violations by Care Access in the VALOR trial. The FDA inspection lasted from October 2nd to October 10th, 2023, and was an in-depth review of Care Access’s contributions to the trial, including with respect to general GCP requirements, patient safety, and data integrity.

Earlier this year, Pfizer discontinued over 3,000 participants at Care Access sites on the study due to alleged GCP violations. Care Access disagreed with Pfizer’s decision and rejected the allegations. The lack of any findings by the FDA investigator is wholly consistent with Care Access’s assertions that there were no GCP violations.

“We couldn’t be prouder of our team,” said Care Access CEO Ahmad Namvargolian. “This confirms what we’ve known all along about Care Access’ outstanding systems and controls to ensure regulatory compliance and patient safety on all the studies it performs. We’re very glad to have had the opportunity finally to undergo this independent, searching review by an FDA expert, which confirmed what we’ve always said about our performance on the VALOR trial and beyond.”

The Pfizer VALOR study is ongoing and seeks to determine the safety and efficacy of a potential Vaccine for Lyme Disease. Care Access had deployed its unique decentralized model to bring this study to previously unreachable communities that are most impacted by Lyme Disease. With a fleet of mobile research vehicles and a team of traveling research professionals, Care Access specializes in having clinical research meet the needs of a community, not the other way around.

About Care Access

Care Access is a global research company helping to accelerate the arrival of new medicines. With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 20 biopharmaceutical companies. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation.

To learn more visit www.careaccess.com.

责任编辑:admin

相关阅读

其它网友:蓅姩媣栺圊舂
评论:昨天去市里参加放鸽子比赛,结果就我一个人去了。

百度网友:经年°reminis
评论:天长地久、根本没有;海枯石烂、纯属扯蛋。

天猫网友:Lost love / 失爱
评论:做一个单纯的人,走一段幸福的路。

网易网友:m/m  撕心裂肺°
评论:当今社会别结婚,结了又离多麻烦.

凤凰网友:memory’青春
评论:法国有个圣女,叫贞德。中国有好多剩女,是真的。

猫扑网友:Pawonx-爱离殇
评论:人之所以活得累是因为:放不下架子,撕不开面子,解不开情节。

搜狐网友:关于病态美beauty ×
评论:我们这个年龄,更多的是练爱而不是恋爱。

本网网友:不帶這么玩的
评论:爱由一个笑容开始,用一个吻来成长,用一滴眼泪来结束。

天涯网友:︶別致微笑ゞ
评论:信就是信,不信就是不信,你丫的还微信。

淘宝网友:Alexandr 嫁衣°
评论:一开始学习就不开心了,一不开心就不学习了,一不学习就开心了,一开心就一天过去了。